Goldman Sachs’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.4M | Sell |
353,097
-47,261
| -12% | -$1.06M | ﹤0.01% | 3325 |
|
|
2025
Q4 | $9.21M | Sell |
400,358
-76,580
| -16% | -$2.52M | ﹤0.01% | 3169 |
|
|
2025
Q3 | $14.3M | Buy |
476,938
+50,944
| +12% | +$1.53M | ﹤0.01% | 2604 |
|
|
2025
Q2 | $15.5M | Sell |
425,994
-54,275
| -11% | -$1.96M | ﹤0.01% | 2356 |
|
|
2025
Q1 | $17.4M | Sell |
480,269
-73,401
| -13% | -$3.05M | ﹤0.01% | 2156 |
|
|
2024
Q4 | $23.3M | Buy |
553,670
+47,160
| +9% | +$2.34M | ﹤0.01% | 1982 |
|
|
2024
Q3 | $28.1M | Sell |
506,510
-123,004
| -20% | -$6.27M | ﹤0.01% | 1750 |
|
|
2024
Q2 | $25.9M | Buy |
629,514
+265,392
| +73% | +$11.3M | ﹤0.01% | 1678 |
|
|
2024
Q1 | $17M | Buy |
364,122
+209,070
| +135% | +$9.86M | ﹤0.01% | 1983 |
|
|
2023
Q4 | $7.41M | Sell |
155,052
-236,251
| -60% | -$9.16M | ﹤0.01% | 2793 |
|
|
2023
Q3 | $13.9M | Sell |
391,303
-145,425
| -27% | -$5.76M | ﹤0.01% | 2099 |
|
|
2023
Q2 | $24.8M | Buy |
536,728
+91,721
| +21% | +$4.25M | 0.01% | 1669 |
|
|
2023
Q1 | $17.8M | Sell |
445,007
-669,311
| -60% | -$28.7M | ﹤0.01% | 1910 |
|
|
2022
Q4 | $51.6M | Buy |
1,114,318
+103,130
| +10% | +$4.06M | 0.01% | 1147 |
|
|
2022
Q3 | $41.9M | Buy |
1,011,188
+151,113
| +18% | +$7.77M | 0.01% | 1240 |
|
|
2022
Q2 | $51.3M | Buy |
860,075
+92,834
| +12% | +$5.71M | 0.01% | 1110 |
|
|
2022
Q1 | $55.7M | Buy |
767,241
+41,563
| +6% | +$2.89M | 0.01% | 1183 |
|
|
2021
Q4 | $61M | Buy |
725,678
+219,470
| +43% | +$17.9M | 0.01% | 1180 |
|
|
2021
Q3 | $45.7M | Sell |
506,208
-136,442
| -21% | -$12.3M | 0.01% | 1349 |
|
|
2021
Q2 | $61.3M | Sell |
642,650
-115,471
| -15% | -$12M | 0.01% | 1096 |
|
|
2021
Q1 | $86.3M | Sell |
758,121
-114,707
| -13% | -$15.6M | 0.02% | 746 |
|
|
2020
Q4 | $121M | Buy |
872,828
+435,332
| +100% | +$51.6M | 0.03% | 526 |
|
|
2020
Q3 | $36M | Sell |
437,496
-8,494
| -2% | -$704K | 0.01% | 1256 |
|
|
2020
Q2 | $34.9M | Sell |
445,990
-9,532
| -2% | -$631K | 0.01% | 1243 |
|
|
2020
Q1 | $20.2M | Sell |
455,522
-41,884
| -8% | -$2.17M | 0.01% | 1500 |
|
|
2019
Q4 | $21.2M | Buy |
497,406
+101,482
| +26% | +$4.19M | 0.01% | 1803 |
|
|
2019
Q3 | $16.9M | Sell |
395,924
-8,256
| -2% | -$449K | ﹤0.01% | 1915 |
|
|
2019
Q2 | $25.7M | Sell |
404,180
-91,229
| -18% | -$5.81M | 0.01% | 1652 |
|
|
2019
Q1 | $34.4M | Buy |
495,409
+194,542
| +65% | +$11.1M | 0.01% | 1424 |
|
|
2018
Q4 | $13.1M | Sell |
300,867
-3,543
| -1% | -$194K | ﹤0.01% | 2144 |
|
|
2018
Q3 | $23.2M | Buy |
304,410
+61,770
| +25% | +$5.02M | 0.01% | 1812 |
|
|
2018
Q2 | $18.7M | Sell |
242,640
-285,108
| -54% | -$18.4M | 0.01% | 1926 |
|
|
2018
Q1 | $26.9M | Buy |
527,748
+44,216
| +9% | +$2.23M | 0.01% | 1607 |
|
|
2017
Q4 | $22.4M | Sell |
483,532
-135,279
| -22% | -$6.63M | 0.01% | 1851 |
|
|
2017
Q3 | $33M | Buy |
618,811
+79,050
| +15% | +$4.68M | 0.01% | 1593 |
|
|
2017
Q2 | $33.5M | Buy |
539,761
+122,321
| +29% | +$7.37M | 0.01% | 1539 |
|
|
2017
Q1 | $28.3M | Buy |
417,440
+14,583
| +4% | +$1.11M | 0.01% | 1636 |
|
|
2016
Q4 | $28.3M | Sell |
402,857
-238,761
| -37% | -$16.9M | 0.01% | 1709 |
|
|
2016
Q3 | $45.5M | Buy |
641,618
+5,185
| +0.8% | +$331K | 0.01% | 1277 |
|
|
2016
Q2 | $31.1M | Buy |
636,433
+163,786
| +35% | +$10.6M | 0.01% | 1457 |
|
|
2016
Q1 | $29.9M | Buy |
472,647
+76,049
| +19% | +$4.98M | 0.01% | 1426 |
|
|
2015
Q4 | $44.5M | Sell |
396,598
-141,591
| -26% | -$14.2M | 0.01% | 1215 |
|
|
2015
Q3 | $51.8M | Buy |
538,189
+343,524
| +176% | +$39.3M | 0.02% | 1026 |
|
|
2015
Q2 | $19.9M | Sell |
194,665
-11,907
| -6% | -$925K | 0.01% | 1797 |
|
|
2015
Q1 | $12.8M | Sell |
206,572
-84,530
| -29% | -$4.7M | ﹤0.01% | 2088 |
|
|
2014
Q4 | $12.8M | Buy |
291,102
+83,029
| +40% | +$3.8M | ﹤0.01% | 2159 |
|
|
2014
Q3 | $11.8M | Buy |
208,073
+18,210
| +10% | +$916K | ﹤0.01% | 2235 |
|
|
2014
Q2 | $8.52M | Buy |
189,863
+64,815
| +52% | +$2.67M | ﹤0.01% | 2511 |
|
|
2014
Q1 | $6.11M | Buy |
+125,048
| New | +$6.44M | ﹤0.01% | 2791 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Goldman Sachs's RARE Position: Q1 2026 in Review
Goldman Sachs reduced its Ultragenyx Pharmaceutical (RARE) stake by 12% in Q1 2026, selling an estimated $1.06M and leaving 353,097 shares worth $7.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3325.
Goldman Sachs first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $121M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Goldman Sachs held 353,097 shares of Ultragenyx Pharmaceutical worth $7.4M as of Q1 2026.
- Goldman Sachs sold 47,261 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.06M.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3325 holding.
- Goldman Sachs first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
- Goldman Sachs's Ultragenyx Pharmaceutical position peaked at $121M in Q4 2020.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.